[1] |
WAKELEE H, ALTORKI N, FELIP E, et al. PL03.09 IMpower010: overall survival interim analysis of a phase Ⅲ study of atezolizumab vs best supportive care in resected NSCLC[J]. J Thorac Oncol, 2022, 17(9): S2.
|
[2] |
O’BRIEN M, PAZ-ARES L, MARREAUD S, et al. Pembrolizumab versus placebo as adjuvant therapy for completely resected stage ⅠB-ⅢA non-small cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial[J]. Lancet Oncol, 2022, 23(10): 1274-1286.
doi: 10.1016/S1470-2045(22)00518-6
|
[3] |
PAZ-ARES L, O’BRIEN M E R, MAUER M, et al. Pembrolizumab (pembro) versus placebo for early-stage non-small cell lung cancer (NSCLC) following complete resection and adjuvant chemotherapy (chemo) when indicated: randomized, triple-blind, phase Ⅲ EORTC-1416-LCG/ETOP 8-15-PEARLS/KEYNOTE-091 study[J]. Ann Oncol, 2022, 33(4): 451-453.
doi: 10.1016/j.annonc.2022.02.224
|
[4] |
PASSARO A. Invited Discussant 1529MO, 930MO and 933MO[EB/OL]. (2022-09-12)[2023-02-02]. https://oncologypro.esmo.org/meeting-resources/esmo-congress/invited-discussant-1529mo-930mo-and-933mo.
|
[5] |
PROVENCIO M, SERNA R, NADAL E, et al. PL03.12 progression free survival and overall survival in NADIM Ⅱ study[J]. J Thorac Oncol, 2022, 17(9): S2-S3.
|
[6] |
TSUBOI M, WU Y L, GROHE C, et al. Osimertinib as adjuvant therapy in patients (pts) with resected EGFR-mutated (EGFRm) stage ⅠB-ⅢA non-small cell lung cancer (NSCLC): updated results from ADAURA[J]. Ann Oncol, 2022, 33: S1413-S1414.
|
[7] |
YUE D S, XU S D, WANG Q, et al. Updated overall survival and exploratory analysis from randomized, phase Ⅱ EVAN study of erlotinib versus vinorelbine plus cisplatin adjuvant therapy in stage ⅢA epidermal growth factor receptor + non-small cell lung cancer[J]. J Clin Oncol, 2022, 40(34): 3912-3917.
doi: 10.1200/JCO.22.00428
|
[8] |
ZHONG W Z, CHEN K N, CHEN C, et al. Erlotinib versus gemcitabine plus cisplatin as neoadjuvant treatment of stage ⅢA-N2 EGFR-mutant non-small cell lung cancer (EMERGING-CTONG 1103): a randomized phase Ⅱ study[J]. J Clin Oncol, 2019, 37(25): 2235-2245.
|
[9] |
LYU C, FANG W, JIAO W, et al. Osimertinib as neoadjuvant therapy in patients with EGFR mutated resectable stage Ⅱ-ⅢB lung adenocarcinoma (NEOS): updated results[J]. Ann Oncol, 2022, 33: S71-S72.
|
[10] |
TSUBOI M, WEDER W, ESCRIU C, et al. Neoadjuvant osimertinib with/without chemotherapy versus chemotherapy alone for EGFR-mutated resectable non-small cell lung cancer: NeoADAURA[J]. Future Oncol, 2021, 17(31): 4045-4055.
doi: 10.2217/fon-2021-0549
|
[11] |
FORDE P M, SPICER J, LU S, et al. Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer[J]. N Engl J Med, 2022, 386(21): 1973-1985.
doi: 10.1056/NEJMoa2202170
|
[12] |
SHI Y K, CHEN G, WANG X, et al. Furmonertinib versus gefitinib in treatment-naïve EGFR mutated non-small cell lung cancer: a randomized, double-blind, multi-center, phase Ⅲ study (FURLONG)[J]. Ann Oncol, 2022, 33: S27.
|
[13] |
YUANKAI SHI, MD, et al. Central nervous system efficacy of furmonertinib (AST2818) versus gefitinib as first-line treatment for EGFR-mutated NSCLC: results from the FURLONG study[J]. J Thorac Oncol, 2022, 17(11): 1297-1305.
doi: 10.1016/j.jtho.2022.07.1143
|
[14] |
GOLDMAN J, HUANG H K T, CUMMINGS A, et al. MA07.05 phase 1b/2 study of combined HER inhibition in refractory EGFR-mutated metastatic non-small cell lung cancer (NSCLC)[J]. J Thorac Oncol, 2022, 17(9): S68-S69.
|
[15] |
ALEXANDRA YU H, TAN D S W, SMIT E F, et al. Phase (Ph) 1/2a study of CLN-081 in patients (pts) with NSCLC with EGFR exon 20 insertion mutations (ins20)[J]. J Clin Oncol, 2022, 40(16_suppl): 9007.
doi: 10.1200/JCO.2022.40.16_suppl.9007
|
[16] |
16 ZHOU C C, RAMALINGAM S S, KIM T M, et al. Treatment outcomes and safety of mobocertinib in platinum-pretreated patients with EGFR exon 20 insertion-positive metastatic non-small cell lung cancer: a phase 1/2 open-label nonrandomized clinical trial[J]. JAMA Oncol, 2021, 7(12): e214761.
|
[17] |
WANG M, YANG J C H, MITCHELL P, et al. Sunvozertinib for NSCLC patients with EGFR exon 20 insertion mutations: preliminary analysis of WU-KONG6, the first pivotal study[J]. Ann Oncol, 2022, 33: S1003-S1004.
|
[18] |
ZHOU Q, LI J, WANG J, et al. EP08.02-063 SANOVO: a phase 3 study of savolitinib or placebo in combination with osimertinib in patients with EGFR-mutant and MET overexpressed NSCLC[J]. J Thorac Oncol, 2022, 17(9): S429.
|
[19] |
SWAIN S M, SHASTRY M, HAMILTON E. Targeting HER2-positive breast cancer: advances and future directions[J]. Nat Rev Drug Discov, 2023, 22(2): 101-126.
doi: 10.1038/s41573-022-00579-0
|
[20] |
GOLDMAN J W, HORINOUCHI H, CHO B C, et al. Phase 1/1b study of telisotuzumab vedotin (Teliso-V) + osimertinib (Osi), after failure on prior Osi, in patients with advanced, c-Met overexpressing, EGFR-mutated non-small cell lung cancer (NSCLC)[J]. J Clin Oncol, 2022, 40(16_suppl): 9013.
doi: 10.1200/JCO.2022.40.16_suppl.9013
|
[21] |
LI B, SMIT E F, GOTO Y, et al. Primary data from DESTINY-Lung01: a phase 2 trial of trastuzumab deruxtecan (T-DXd) in patients (Pts) with HER2-mutated (HER2m) metastatic non-small cell lung cancer (NSCLC)[C]. ESMO Congress, 2021.
|
[22] |
LI B T, SMIT E F, GOTO Y, et al. Trastuzumab deruxtecan in HER2-mutant non-small cell lung cancer[J]. N Engl J Med, 2022, 386(3): 241-251.
doi: 10.1056/NEJMoa2112431
|
[23] |
FDA. FDA grants accelerated approval to fam-trastuzumab deruxtecan-nxki for HER2-mutant non-small cell lung cancer[EB/OL]. (2022-08-16)[2023-02-02]. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-fam-trastuzumab-deruxtecan-nxki-her2-mutant-non-small-cell-lung.
|
[24] |
ROMÁN M, BARAIBAR I, LÓPEZ I, et al. KRAS oncogene in non-small cell lung cancer: clinical perspectives on the treatment of an old target[J]. Mol Cancer, 2018, 17(1): 33.
doi: 10.1186/s12943-018-0789-x
|
[25] |
RECK M, CARBONE D P, GARASSINO M, et al. Targeting KRAS in non-small cell lung cancer: recent progress and new approaches[J]. Ann Oncol, 2021, 32(9): 1101-1110.
doi: 10.1016/j.annonc.2021.06.001
|
[26] |
JÄNNE P A, RIELY G J, GADGEEL S M, et al. Adagrasib in non-small cell lung cancer harboring a KRAS G12C mutation[J]. N Engl J Med, 2022, 387(2): 120-131.
doi: 10.1056/NEJMoa2204619
|
[27] |
SABARI J K, VELCHETI V, SHIMIZU K, et al. Activity of adagrasib (MRTX849) in brain metastases: preclinical models and clinical data from patients with KRAS G12C-mutant non-small cell lung cancer[J]. Clin Cancer Res, 2022, 28(15): 3318-3328.
doi: 10.1158/1078-0432.CCR-22-0383
|
[28] |
FALCHOOK G, LI B T, MARRONE K A, et al. OA03.03 sotorasib in combination with RMC-4630, a SHP2 inhibitor, in KRAS p.G12C-mutated NSCLC and other solid tumors[J]. J Thorac Oncol, 2022, 17(9): S8.
|
[29] |
ZHOU C, LU Y, KIM S W. Alectinib (ALC) vs crizotinib (CRZ) in Asian patients (pts) with treatment-naïve advanced ALK + non-small cell lung cancer (NSCLC): 5-year update from the phase Ⅲ ALESIA study[J]. Ann Oncol, 2022, 33: S1563.
|
[30] |
CAMIDGE D R, DZIADZIUSZKO R, PETERS S, et al. Updated efficacy and safety data and impact of the EML4-ALK fusion variant on the efficacy of alectinib in untreated ALK-positive advanced non-small cell lung cancer in the global phase Ⅲ ALEX study[J]. J Thorac Oncol, 2019, 14(7): 1233-1243.
doi: 10.1016/j.jtho.2019.03.007
|
[31] |
ZHANG L, FANG W, MIN J, et al. Envonalkib vs crizotinib in treatment-naïve advanced ALK-positive NSCLC: a randomized, multicenter, phase Ⅲ trial[J]. Ann Oncol, 2022, 33: S1564-S1565.
|
[32] |
LEE S M, SCHULZ C, PRABHASH K, et al. IPSOS: Results from a phase Ⅲ study of first-line (1L) atezolizumab (atezo) vs single-agent chemotherapy (chemo) in patients (pts) with NSCLC not eligible for a platinum-containing regimen[J]. Ann Oncol, 2022, 33: S1418-S1419.
|
[33] |
GARASSINO M C, GADGEEL S M, SPERANZA G, et al. KEYNOTE-189 5-year update: first-line pembrolizumab (pembro) + pemetrexed (pem) and platinum vs placebo (pbo) + pem and platinum for metastatic nonsquamous NSCLC[J]. Ann Oncol, 2022, 33: S992-S993.
|
[34] |
NOVELLO S, KOWALSKI D M, LUFT A, et al. Pembrolizumab plus chemotherapy in squamous non-small cell lung cancer: 5-year update of the phase Ⅲ KEYNOTE-407 study[J]. J Clin Oncol, 2023. [Online ahead of print]
|
[35] |
JOHNSON M, CHO B C, LUFT A, et al. Durvalumab (D)±tremelimumab (T) + chemotherapy (CT) in 1L metastatic (m) NSCLC: overall survival (OS) update from POSEIDON after median follow-up (mFU) of approximately 4 years (y)[J]. Ann Oncol, 2022, 33: S1424-S1425.
|
[36] |
RECKAMP K L, REDMAN M W, DRAGNEV K H, et al. Phase Ⅱ randomized study of ramucirumab and pembrolizumab versus standard of care in advanced non-small cell lung cancer previously treated with immunotherapy-lung-MAP S1800A[J]. J Clin Oncol, 2022, 40(21): 2295-2306.
doi: 10.1200/JCO.22.00912
|
[37] |
PROF, SHUN, LU, et al. Sintilimab plus bevacizumab biosimilar IBI305 and chemotherapy for patients with EGFR-mutated non-squamous non-small cell lung cancer who progressed on EGFR tyrosine-kinase inhibitor therapy (ORIENT-31): first interim results from a randomised, double-blind, multicentre, phase 3 trial[J]. Lancet Oncol, 2022, 23(9): 1167-1179.
doi: 10.1016/S1470-2045(22)00382-5
|
[38] |
LEVY B, PAZ-ARES L, RIXE O, et al. MA13.07 TROPION-Lung02: initial results for datopotamab deruxtecan plus pembrolizumab and platinum chemotherapy in advanced NSCLC[J]. J Thorac Oncol, 2022, 17(9): S91.
|
[39] |
RECKAMP K L, REDMAN M W, DRAGNEV K H, et al. Overall survival from a phase Ⅱ randomized study of ramucirumab plus pembrolizumab versus standard of care for advanced non-small cell lung cancer previously treated with immunotherapy: lung-MAP nonmatched substudy S1800A[J]. J Clin Oncol, 2022, 40(suppl 16): 9004.
doi: 10.1200/JCO.2022.40.16_suppl.9004
|